文献速递乳腺病理

乳腺浸润性癌PD-L1 SP142免疫组化判读的观察者间差异:基于全切片图像的79例研究

Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
PubMed 文献 · Arch Pathol Lab Med · 2021-01-01

研究评估了8位乳腺病理专家对79例乳腺浸润性癌全切片图像中PD-L1 SP142免疫组化判读的观察者间一致性。采用IMpassion130标准,以肿瘤区域内1%以上免疫细胞免疫反应性为阳性。结果显示观察者间一致性为中等偏强(κ=0.727),62%病例全部8位判读一致,4%病例(均为小活检)阳性和阴性判读均等分裂。

要点

  • PD-L1 SP142判读在乳腺病理专家间一致性为中等偏强(κ=0.727)。
  • 62%病例8位病理医生判读完全一致,84%病例至少7位一致。
  • 小活检病例中易出现判读分歧,需关注。

核心结论

  • 8位病理医生对乳腺浸润性癌PD-L1 SP142免疫组化判读具有中等偏强的一致性(κ=0.727)。

研究设计与样本

  • 采用计算机随机数生成器选取病例,由8位乳腺病理专家在全切片图像上判读,使用未加权κ计算观察者间差异。

主要发现

  • 共79例病例由8位病理医生评估,观察者间一致性为中等偏强(κ=0.727)。
  • 62%(49/79)病例8位病理医生判读完全一致,84%(66/79)至少7位一致,92%(73/79)至少6位一致。
  • 4%(3/79)病例中,阳性与阴性判读均等分裂,且均为小活检标本。

关键数值与推荐

  • 采用IMpassion130试验标准,将肿瘤区域免疫细胞免疫反应性≥1%定义为阳性。

临床怎么用

  • 乳腺病理专家对PD-L1 SP142判读一致性较好,但小活检标本需注意判读差异。
  • 需进一步研究明确判读差异的原因。

局限性

  • 单机构研究,样本量有限。
  • 未报告判读差异的具体原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: The Ventana programmed death ligand-1 (PD-L1) SP142 immunohistochemical assay (IHC) is approved by the US Food and Drug Administration as the companion diagnostic assay to identify patients with locally advanced or metastatic triple-negative breast cancer for immunotherapy with atezolizumab, a monoclonal antibody targeting PD-L1. OBJECTIVE.—: To determine interobserver variability in PD-L1 SP142 IHC interpretation in invasive breast carcinoma. DESIGN.—: The pathology database was interrogated for all patients diagnosed with primary invasive, locally recurrent, or metastatic breast carcinoma on which PD-L1 SP142 IHC was performed from November 2018 to June 2019 at our institution. A subset of cases was selected using a computerized random-number generator. PD-L1 IHC was evaluated in stromal tumor-infiltrating immune cells using the IMpassion130 trial criteria, with positive cases defined as immunoreactivity in immune cells in 1% or more of the tumor area. IHC was interpreted on whole slide images by staff pathologists with breast pathology expertise. Interobserver variability was calculated using unweighted κ. RESULTS.—: A total of 79 cases were assessed by 8 pathologists. Interobserver agreement was substantial (κ = 0.727). There was complete agreement among all 8 pathologists in 62% (49 of 79) of cases, 7 pathologists or more in 84% (66 of 79) of cases, and 6 pathologists or more in 92% (73 of 79) of cases. In 4% (3 of 79) of cases, all of which were small biopsies, pathologists' interpretations were evenly split between scores of positive and negative. CONCLUSIONS.—: The findings show substantial agreement in PD-L1 SP142 IHC assessment of breast carcinoma cases among 8 pathologists at a single institution. Further study is warranted to define the basis for discrepant results.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Hoda RS, Brogi E, D'Alfonso TM, et al. Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. Arch Pathol Lab Med. 2021. PMID: 33417715. doi:10.5858/arpa.2020-0451-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。